FDA Approves Mimrylo (rusfertide) for Polycythemia Vera
The U.S. Food and Drug Administration has granted approval for Mimrylo (rusfertide), a novel first-in-class hepcidin-mimetic therapy aimed at adults with polycythemia vera. This decision follows positive outcomes observed in the VERIFY phase 3 trial, highlighting Mimrylo's effectiveness in reducing hematocrit levels and decreasing reliance on phleb...
- Published date: 30-08-2026 10:03 AM
The U.S. Food and Drug Administration (FDA) has approved Mimrylo (rusfertide), marking it as the first-in-class therapy specifically designed for adults with polycythemia vera.
This approval is grounded in the VERIFY phase 3 clinical trial results, which demonstrated Mimrylo's potential to effectively manage hematocrit levels in patients whose condition is inadequately controlled by existing treatments.
Mimrylo is a hepcidin-mimetic therapy intended to reduce the need for phlebotomy, offering a new treatment option for this rare blood disorder.
The approval of Mimrylo represents a significant advancement in the management of polycythemia vera, providing clinicians and patients an alternative approach to therapy.